Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2022-10-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于安图生物股票交易异常波动问询函的回复
Regulatory Filings
2022-10-18 Chinese
安图生物股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding abnormal stock price fluctuations over three consecutive trading days in October 2022. It includes the company's self-inspection results, confirmation of no undisclosed material information, and risk warnings to investors. The content focuses on stock trading irregularities and related clarifications, not on financial results, management changes, or other report types. The document length is short (1429 characters) and is a regulatory announcement about stock price behavior, fitting the category of a Regulatory Filing (RNS) rather than a financial report or other specific filing type.
2022-10-18 Chinese
安图生物关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of its share repurchase program. It details the board's approval of the share buyback plan, the price limits, the total amount of shares repurchased to date, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but focuses on the status and specifics of the company's share repurchase activity. This matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback of its own shares.
2022-10-10 Chinese
安图生物关于公司及子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the receipt of medical device registration certificates for the company and its subsidiaries. It details the specific certificates obtained, their validity, and the intended use of the products. The document includes no financial statements, no discussion of financial results, no management commentary on earnings, nor any regulatory certifications or voting results. It is a regulatory announcement about product approvals, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-09-26 Chinese
安图生物关于使用闲置募集资金进行现金管理赎回及进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle raised funds for cash management and the progress of such activities. It includes specifics about the types of cash management products (large certificates of deposit), amounts involved, sources of funds (public convertible bonds and non-public stock issuance), approval procedures, risk analysis, and financial impact. The document references regulatory approvals from the China Securities Regulatory Commission and includes detailed tables of investment projects and cash management transactions. The content is focused on the company's financing and capital management activities, specifically the use of idle raised funds for cash management purposes. It is not a full financial report, audit report, or earnings release, but rather an update on capital/financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9686 characters) and detailed content support this classification with high confidence.
2022-09-06 Chinese
安图生物关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, total amounts paid, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but reports on the company's buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about share repurchases or sales of its own shares.
2022-09-01 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.